Target-based drug discovery for human African trypanosomiasis: Selection of molecular target and chemical matter

Parasitology

Volumn 141, Issue 1, 2014, Pages 28-36

  Gilbert, Ian H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

drug discovery; Human African trypanosomiasis; target product profile; target selection

Indexed keywords

AMPHOTERICIN B; BENZNIDAZOLE; EFLORNITHINE; MEGLUMINE ANTIMONATE; MELARSOPROL; MILTEFOSINE; NIFURTIMOX; ORNITHINE DECARBOXYLASE; PAROMOMYCIN; PENTAMIDINE; PROTEIN N MYRISTOYLTRANSFERASE; STIBOGLUCONATE SODIUM; SURAMIN; ANTITRYPANOSOMAL AGENT; DRUG DOSAGE FORM;

AFRICAN TRYPANOSOMIASIS; ARTICLE; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG RESISTANCE; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; GENE SILENCING; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT GENE; NONHUMAN; PARASITE SURVIVAL; PARASITE VIABILITY; PHARMACOKINETICS; PHARMACOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RNA INTERFERENCE; TRYPANOSOMA BRUCEI; TRYPANOSOMATID INFECTION; BIOAVAILABILITY; CHEMISTRY; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PARASITOLOGY; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA; TRYPANOSOMA RHODESIENSE; TRYPANOSOMIASIS, AFRICAN;

BIOLOGICAL AVAILABILITY; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG RESISTANCE; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 84891854133     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182013001017     Document Type: Article

References (42)

1. Arrowsmith, J. (2011a). Phase III and submission failures: 2007-2010. Nature Reviews Drug Discovery 10, 87
2. Arrowsmith, J. (2011b). Trial watch: Phase II failures: 2008-2010. Nature Reviews Drug Discovery 10, 328-329
3. Barrett, M. P. (1999). The fall and rise of sleeping sickness. Lancet 353, 1113-1114
4. Barrett, M. P. (2006). The rise and fall of sleeping sickness. Lancet 367, 1377-1378
5. Barrett, M. P. and Croft, S. L. (2012). Management of trypanosomiasis and leishmaniasis. British Medical Bulletin 104, 175-196
6. Barrett, M. P., Mottram, J. C. and Coombs, G. H. (1999). Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Trends in Microbiology 7, 82-88
7. Beverley, S.M. (2003). Protozomics: Trypanosomatid parasite genetics comes of age. Nature Reviews Genetics 4, 11-19
8. Brand, S., Cleghorn, L. A., McElroy, S. P., Robinson, D. A., Smith, V. C., Hallyburton, I., Harrison, J. R., Norcross, N. R., Spinks, D., Bayliss, T., Norval, S., Stojanovski, L., Torrie, L. S., Frearson, J. A., Brenk, R., Fairlamb, A. H., Ferguson, M. A., Read, K. D., Wyatt, P. G. and Gilbert, I. H. (2012). Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. Journal of Medicinal Chemistry 55, 140-152
9. Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J. A. and Wyatt, P. G. (2008). Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem 3, 435-444
10. Brun, R., Don, R., Jacobs, R. T., Wang, M. Z. and Barrett, M. P. (2011). Development of novel drugs for human African trypanosomiasis. Future Microbiology 6, 677-691
11. Cleghorn, L. A. T., Woodland, A., Collie, I., Torrie, L., Norcross, N., Luksch, T.,Mpamhanga, C., Walker, R. G., Mottram, J. C., Brenk, R., Frearson, J. A., Gilbert, I. H. and Wyatt, P. G. (2011). Identification of inhibitors of the Leishmania cdc-related protein kinase CRK3. ChemMedChem 6, 2214-2224
12. Eastman, R. T., Buckner, F. S., Yokoyama, K., Gelb, M. H. and Van Voorhis, W. C. (2006). Fighting parasitic disease by blocking protein farnesylation. Journal of Lipid Research 47, 233-240
13. Edfeldt, F. N., Folmer, R. H. and Breeze, A. L. (2011). Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discovery Today 16, 284-287
14. Frearson, J. A., Brand, S., McElroy, S. P., Cleghorn, L. A. T., Smid, O., Stojanovski, L., Price, H. P., Guther, M. L. S., Torrie, L. S., Robinson, D. A., Hallyburton, I., Mpamhanga, C. P., Brannigan, J. A., Wilkinson, A. J., Hodgkinson, M., Hui, R., Qiu, W., Raimi, O. G., Van Aalten, D. M. F., Brenk, R., Gilbert, I. H., Read, K. D., Fairlamb, A. H., Ferguson, M. A. J., Smith, D. F. and Wyatt, P. G. (2010). N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464, 728-732
15. Frearson, J. A., Wyatt, P. G., Gilbert, I.H. and Fairlamb, A. H. (2007). Target assessment for antiparasitic drug discovery. Trends in Parasitology 23, 589-595
16. Gilbert, I H., Leroy, D. and Frearson, J. A. (2011). Finding new hits in neglected disease projects: Target or phenotypic based screening? Current Topics in Medicinal Chemistry 11, 1284-1291
17. Gillespie, J. R., Yokoyama, K., Lu, K., Eastman, R. T., Bollinger, J. G., Van Voorhis, W. C., Gelb, M. H. and Buckner, F. S. (2007). C-Terminal proteolysis of prenylated proteins in trypanosomatids and RNAinterference of enzymes required for the post-Translational processing pathway of farnesylated proteins. Molecular and Biochemical Parasitology 153, 115-124
18. Gleeson, M. P., Hersey, A., Montanari, D. and Overington, J. (2011). Probing the links between in vitro potency, ADMET and physicochemical parameters. Nature Reviews Drug Discovery 10, 197-208
19. Hann, M. M. (2011). Molecular obesity, potency and other addictions in drug discovery. MedChemComm 2, 349-355
20. Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., Decrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R.W., Greene, N., Huang, E., Krieger-Burke, T., Loesel, J., Wager, T., Whiteley, L. and Zhang, Y. (2008). Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorganic and Medicinal Chemistry Letters 18, 4872-4875
21. Jacobs, R. T., Nare, B. and Phillips, M. A. (2011). State of the art in African trypanosome drug discovery. Current Topics in Medicinal Chemistry 11, 1255-1274
22. Kelder, J., Grootenhuis, P. D. J., Bayada, D. M., Delbressine, L. P. C. and Ploemen, J. P. (1999). Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharmaceutical Research 16, 1514-1519
23. Kola, I and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 3, 711-715
24. Krasowski, A., Muthas, D., Sarkar, A., Schmitt, S. and Brenk, R. (2011). DrugPred: A structure-based approach to predict protein druggability developed using an extensive nonredundant data set. Journal of Chemical Information and Modeling 51, 2829-2842
25. Leeson, P. D. and Springthorpe, B. (2007). The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Reviews Drug Discovery 6, 881-890
26. Lipinski, C. A., Lombardo, F., Dominy, B.W. and Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 23, 3-25
27. Lipinski, C. A., Lombardo, F., Dominy, B.W. and Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 46, 3-26
28. Lovering, F., Bikker, J. and Humblet, C. (2009). Escape from Flatland: Increasing saturation as an approach to improving clinical success. Journal of Medicinal Chemistry 52, 6752-6756
29. Motyka, S. A. and Englund, P. T. (2004). RNA interference for analysis of gene function in trypanosomatids. Current Opinion in Microbiology 7, 362-368
30. Nadin, A., Hattotuwagama, C. and Churcher, I. (2012). Lead-oriented synthesis: A new opportunity for synthetic chemistry. Angewandte Chemie-International Edition 51, 1114-1122
31. Panethymitaki, C., Bowyer, P.W., Price, H. P., Leatherbarrow, R. J., Brown, K. A. and Smith, D. F. (2006). Characterization and selective inhibition of myristoyl-CoA: Protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major. Biochemical Journal 396, 277-285
32. Price, H. P., Menon, M. R., Panethymitaki, C., Goulding, D., McKean, P. G. and Smith, D. F. (2003). Myristoyl-CoA:protein Nmyristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites. Journal of Biological Chemistry 278, 7206-7214
33. Price, H. P., Guther, M. L. S., Ferguson, M. A. J. and Smith, D. F. (2010). Myristoyl-CoA:protein N-myristoyltransferase depletion in trypanosomes causes avirulence and endocytic defects. Molecular and Biochemical Parasitology 169, 55-58
34. Ritchie, T J. and MacDonald, S. J. F. (2009). The impact of aromatic ring count on compound developability-Are too many aromatic rings a liability in drug desigñ Drug Discovery Today 14, 1011-1020
35. Ritchie, T. J., MacDonald, S. J. F., Young, R. J. and Pickett, S. D. (2011). The impact of aromatic ring count on compound developability: Further insights by examiing carbo-And hetero-Aromatic and -Aliphatic ring types. Drug Discovery Today 16, 164-171
36. Spinks, D., Torrie, L. S., Thompson, S., Harrison, J. R., Frearson, J. A., Read, K. D., Fairlamb, A. H., Wyatt, P. G. and Gilbert, I.H. (2012). Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors. ChemMedChem 7, 95-106
37. Ullu, E., Tschudi, C. and Chakraborty, T. (2004). RNA interference in protozoan parasites. Cellular Microbiology 6, 509-519
38. Velez, N., Brautigam, C. A. and Phillips, M. A. (2013). Trypanosoma brucei S-Adenosylmethionine decarboxylase N terminus is essential for allosteric activation by the regulatory subunit prozyme. Journal of Biological Chemistry 288, 5232-5240
39. Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A. and Will, Y. (2010a). Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chemical Neuroscience 1, 420-434
40. Wager, T. T., Hou, X., Verhoest, P. R. and Villalobos, A. (2010b). Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chemical Neuroscience 1, 435-449
41. Wilkinson, S. R. and Kelly, J. M. (2009). Trypanocidal drugs: Mechanisms, resistance and new targets. Expert Reviews in Molecular Medicine 11, e31
42. Wyatt, P. G., Gilbert, I. H., Read, K. D. and Fairlamb, A. H. (2011). Target validation: Linking target and chemical properties to desired product profile. Current Topics in Medicinal Chemistry 11, 1275-1283